IgA Antibodies Reveal Covert Infection With Mpox Virus in People Living With HIV in the Community: A Prospective Longitudinal Cohort Survey

Abstract

Covert mpox virus (MPXV) infection among people living with HIV (PLWH) remains poorly understood. This study aimed to investigate undetected MPXV infections through seroepidemiological analysis. We recruited 148 PLWH during July 2–9, 2023 (baseline), with 60 and 148 participants returning for 4- and 14-month follow-ups, respectively. PCR testing showed that all saliva and blood samples were negative for MPXV-DNA. The titers of IgG, IgA, and IgM were evaluated using ELISA with virions. MPXV-IgA and IgM were undetectable, 15 participants born before 1980 had low MPXV-IgG at baseline. At 14 months, 10 participants (6.8%) showed increased MPXV-IgG titers. All seroconverters had detectable neutralizing antibodies, and nine were MPXV-IgA positive. Further results showed that IgG seropositivity against MPXV proteins (A29L, A35R, B6R, E8L, H3L, and M1R) ranged from 0% to 80%, while IgA seropositivity ranged from 0% to 60% among the 10 participants at the 14-month. The B6R and E8L combination showed IgG detection comparable to whole virions, while E8L and H3L combination increased IgA seropositivity to 70%. The occurrence of MPXV covert infection among PLWH underscores the need to improve surveillance strategies in the community. The presence of MPXV-IgA in blood may offer a preliminary temporal signal of MPXV infection.

Keywords

covert transmission / MPXV / people living with HIV / undetected infection

References

[1] F. B. Buesching, D. M. Steininger, and D. J. Veit, “Governing Digital Crisis Responses: Platform Standards and the Dilemma of COVID-19 Contact Tracing,” Journal of Business Economics 93, no. 1–2 (2023): 267–323.

[2] C. S. Saldana, C. F. Kelley, B. M. Aldred, et al., “Mpox and HIV: A Narrative Review,” Current HIV/AIDS Reports 20, no. 4 (2023): 261–269.

[3] O. Mitja, A. Alemany, M. Marks, et al., “Mpox in People With Advanced HIV Infection: A Global Case Series,” Lancet 401, no. 10380 (2023): 939–949.

[4] A. Patel, J. Bilinska, J. C. H. Tam, et al., “Clinical Features and Novel Presentations of Human Monkeypox in a Central London Centre During the 2022 Outbreak: Descriptive Case Series,” BMJ 378 (2022): e072410.

[5] A. Reda, A. E. El-Qushayri, and J. Shah, “Asymptomatic Monkeypox Infection: A Call for Greater Control of Infection and Transmission,” Lancet Microbe 4, no. 1 (2023): e15–e16.

[6] C. J. Waddell, T. D. Filardo, N. Prasad, et al., “Possible Undetected Mpox Infection Among Persons Accessing Homeless Services and Staying in Encampments—San Francisco, California, October-November 2022,” MMWR Morbidity and Mortality Weekly Report 72, no. 9 (2023): 227–231.

[7] P. F. Salvo, A. Sanfilippo, G. Baldin, et al., “Investigating Seroprevalence of IgG Antibodies Against Monkeypox Virus (MPXV) in a Cohort of People Living With HIV (PLWH) in Rome, During the 2022 Outbreak: Moving Beyond Traditional At-Risk Populations,” Travel Medicine and Infectious Disease 62 (2024): 102757.

[8] I. De Baetselier, C. Van Dijck, C. Kenyon, et al., “Retrospective Detection of Asymptomatic Monkeypox Virus Infections Among Male Sexual Health Clinic Attendees in Belgium,” Nature Medicine 28, no. 11 (2022): 2288–2292.

[9] L. M. Masirika, J. C. Udahemuka, L. Schuele, et al., “Ongoing Mpox Outbreak in Kamituga, South Kivu Province, Associated With Monkeypox Virus of a Novel Clade I Sub-Lineage, Democratic Republic of the Congo, 2024,” Euro Surveillance 29, no. 11 (2024): 2400106.

[10] G. M. Allan-Blitz LT, P. Adamson, I. Park, et al., “A Position Statement on Mpox as a Sexually Transmitted Disease,” Clinical Infectious Diseases 76, no. 8 (2023): 1508–1512.

[11] “General's Statement at the Press Conference Following IHR Emergency Committee Regarding the Multi-Country Outbreak of Monkeypox,” WHO Director, accessed 23 July, 2022, https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi–country-outbreak-of-monkeypox–23-july-2022.

[12] “General Declares Mpox Outbreak a Public Health Emergency of International Concern,” WHO Director, accessed 14 August, 2024, https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern.

[13] F. Colavita, G. Matusali, V. Mazzotta, et al., “Profiling the Acute Phase Antibody Response Against Mpox Virus in Patients Infected During the 2022 Outbreak,” Journal of Medical Virology 95, no. 6 (2023): e28851.

[14] L. Guo, R. Song, Q. Zhang, et al., “Profiling of Viral Load, Antibody and Inflammatory Response of People With Monkeypox During Hospitalization: A Prospective Longitudinal Cohort Study in China,” EBioMedicine 106 (2024): 105254.

[15] I. Moraes-Cardoso, S. Benet, J. Carabelli, et al., “Immune Responses Associated With Mpox Viral Clearance in Men With and Without HIV in Spain: A Multisite, Observational, Prospective Cohort Study,” Lancet Microbe 5, no. 8 (2024): 100859.

[16] F. Fenner, “A Successful Eradication Campaign. Global Eradication of Smallpox,” Reviews of Infectious Diseases 4, no. 5 (1982): 916–930.

[17] D. Moschese, G. Pozza, D. Mileto, et al., “Isolation of Viable Monkeypox Virus From Anal and Urethral Swabs, Italy, May to July 2022,” Euro Surveillance 27, no. 36 (2022): 2200675.

[18] The Lancet, “Mpox: The Need for a Coordinated International Response,” Lancet 404, no. 10454 (2024): 725.

[19] L. Wang and G. F. Gao, “More Mpox Data Are Needed to Better Respond to the Public Health Emergency of International Concern,” Lancet 404, no. 10461 (2024): 1399–1400.

[20] J. R. Wang, “Mpox Surveillance: The Need for Enhanced Testing and Genomic Epidemiology,” Lancet 404, no. 10465 (2024): 1784–1785.

[21] C. Agusti, H. Martinez-Riveros, A. Hernandez-Rodriguez, et al., “Self-Sampling Monkeypox Virus Testing in High-Risk Populations, Asymptomatic or With Unrecognized Mpox, in Spain,” Nature Communications 14, no. 1 (2023): 5998.

[22] M. R. Golden, O. O. Soge, M. Mills, et al., “Asymptomatic and Subclinical Mpox: An Association With Modified Vaccinia Ankara Vaccine,” Sexually Transmitted Diseases 51, no. 5 (2024): 342–347.

[23] Y. C. Manabe, J. Hardick, K. Uhteg, et al., “Retrospective Monkeypox Virus Surveillance Among Male Users of I Want the Kit in Maryland, United States,” Clinical Infectious Diseases 79, no. 1 (2024): 138–140.

[24] V. M. Ferre, A. Bachelard, M. Zaidi, et al., “Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France,” Annals of Internal Medicine 175, no. 10 (2022): 1491–1492.

[25] J. J. Esposito, J. F. Obijeski, and J. H. Nakano, “Serological Relatedness of Monkeypox, Variola, and Vaccinia Viruses,” Journal of Medical Virology 1, no. 1 (1977): 35–47.

[26] U. Marcus, J. Michel, N. Lunchenkov, et al., “A Seroprevalence Study Indicates a High Proportion of Clinically Undiagnosed MPXV Infections in Men Who Have Sex With Men in Berlin, Germany,” BMC Infectious Diseases 24, no. 1 (2024): 1153.

[27] P. Pathela, M. B. Townsend, E. J. Kopping, et al., “Serological Evidence of Mpox Virus Infection During Peak Mpox Transmission in New York City, July to August 2022,” Journal of Infectious Diseases 230, no. 5 (2024): 1102–1109.

[28] K. L. Karem, M. Reynolds, Z. Braden, et al., “Characterization of Acute-Phase Humoral Immunity to Monkeypox: Use of Immunoglobulin M Enzyme-Linked Immunosorbent Assay for Detection of Monkeypox Infection During the 2003 North American Outbreak,” Clinical and Diagnostic Laboratory Immunology 12, no. 7 (2005): 867–872.

[29] Q. Ye, D. Zhang, R. R. Zhang, et al., “A Penta-Component Mpox mRNA Vaccine Induces Protective Immunity in Nonhuman Primates,” Nature Communications 15, no. 1 (2024): 10611.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.